- Home
- BIDU vs CANF Comparison
BIDU vs CANF Comparison
Compare BIDU & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIDU
- CANF
- Stock Information
- Founded
- BIDU 2000
- CANF 1994
- Country
- BIDU China
- CANF Israel
- Employees
- BIDU N/A
- CANF N/A
- Industry
- BIDU Computer Software: Programming Data Processing
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- BIDU Technology
- CANF Health Care
- Exchange
- BIDU Nasdaq
- CANF Nasdaq
- Market Cap
- BIDU N/A
- CANF 7.9M
- IPO Year
- BIDU 2005
- CANF N/A
- Fundamental
- Price
- BIDU $82.59
- CANF $1.20
- Analyst Decision
- BIDU Buy
- CANF Strong Buy
- Analyst Count
- BIDU 11
- CANF 2
- Target Price
- BIDU $116.55
- CANF $14.00
- AVG Volume (30 Days)
- BIDU 5.5M
- CANF 413.8K
- Earning Date
- BIDU 05-15-2025
- CANF 04-29-2025
- Dividend Yield
- BIDU N/A
- CANF N/A
- EPS Growth
- BIDU 19.61
- CANF N/A
- EPS
- BIDU 9.04
- CANF N/A
- Revenue
- BIDU $18,238,549,935.00
- CANF $674,000.00
- Revenue This Year
- BIDU $5.05
- CANF $461.72
- Revenue Next Year
- BIDU $5.86
- CANF N/A
- P/E Ratio
- BIDU $9.14
- CANF N/A
- Revenue Growth
- BIDU N/A
- CANF N/A
- 52 Week Low
- BIDU $74.71
- CANF $1.22
- 52 Week High
- BIDU $116.25
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- BIDU 42.10
- CANF 37.12
- Support Level
- BIDU $81.81
- CANF $1.22
- Resistance Level
- BIDU $86.73
- CANF $1.82
- Average True Range (ATR)
- BIDU 3.55
- CANF 0.13
- MACD
- BIDU -0.41
- CANF -0.02
- Stochastic Oscillator
- BIDU 43.78
- CANF 3.13
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).